YOLT-101
Another single-infusion #BaseEditor therapy for Heterozygous Familial Hypercholesterolemia
From #YolTech Therapeutics

0.6 mg/kg N=3
Being effective in 1 wk
Sustained 70% ⬇️plasma PCSk9 & 50% ⬇️LDL-C till 16-wk

medRxiv 2025
www.medrxiv.org/content/10.1...

YolTech Therapeutics Achieves FDA Clearance for Revolutionary Gene-Editing Therapy YOLT-101 YolTech Therapeutics has received FDA approval for YOLT-101, a groundbreaking gene-editing therapy aimed at treating familial hypercholesterolemia, marking a pivotal moment in biotechnology.

YolTech Therapeutics Achieves FDA Clearance for Revolutionary Gene-Editing Therapy YOLT-101 #Shanghai #None #Gene_Editing #YolTech #YOLT-101

China Fast-Follower Competition Reaches Clinical CRISPR There is panic among Western biotech that Chinese competitors will eat their lunch with their capital-efficient fast-follower strategy which...

#YolTech announcement today forces me to address #China biotech competition (blog): rnaitherapeutics.blogspot.com/2025/04/chin...

$VERV #CRISPR

YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic...

#Yoltech with #China investigator-initiated n=6 #PCSK9 base editor data.

Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.

www.prnewswire.com/news-release...

YolTech's YOLT-101 Offers Hope for Familial Hypercholesterolemia Patients with Novel Therapy YolTech Therapeutics reveals positive interim findings from a trial on YOLT-101, an innovative treatment for familial hypercholesterolemia that significantly lowers cholesterol levels.

YolTech's YOLT-101 Offers Hope for Familial Hypercholesterolemia Patients with Novel Therapy #China #Shanghai #YolTech #YOL-101 #Familial_Hypercholesterolemia

YolTech Therapeutics Receives FDA Orphan Drug Designations for Innovative Gene Therapy YOLT-203 YolTech Therapeutics has achieved significant FDA designations for its gene therapy YOLT-203, aimed at treating primary hyperoxaluria type 1, promising hope for affected patients.

YolTech Therapeutics Receives FDA Orphan Drug Designations for Innovative Gene Therapy YOLT-203 #China #Shanghai #FDA_Approval #YolTech #YOLT-203